US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6713061B1
(en)
|
1996-03-12 |
2004-03-30 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
WO1997033904A1
(en)
|
1996-03-12 |
1997-09-18 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US7357927B2
(en)
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
EP0920505B1
(de)
*
|
1996-08-16 |
2008-06-04 |
Schering Corporation |
Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
|
GB9625074D0
(en)
*
|
1996-12-02 |
1997-01-22 |
Pharmacia & Upjohn Spa |
Receptor belonging to the TNF/NGF receptor family
|
CA2308114A1
(en)
*
|
1997-10-21 |
1999-04-29 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
|
US6689607B2
(en)
|
1997-10-21 |
2004-02-10 |
Human Genome Sciences, Inc. |
Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
US6503184B1
(en)
|
1997-10-21 |
2003-01-07 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
EP1053321A1
(de)
*
|
1998-02-09 |
2000-11-22 |
Genentech, Inc. |
Tnf-rezeptor homolog und dessen kodierende nukleinsäuren
|
JP2002537769A
(ja)
|
1999-02-26 |
2002-11-12 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒトエンドカインαおよび使用方法
|
DK1196186T3
(da)
*
|
1999-07-12 |
2008-03-03 |
Genentech Inc |
Stimulering eller inhibering af angiogenese og kardiovaskularisation med tumornekrosefaktorligand/receptorhomologer
|
CA2405550A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
ATE494304T1
(de)
|
2000-06-16 |
2011-01-15 |
Human Genome Sciences Inc |
Immunspezifisch bindende antikörper gegen blys
|
MXPA03010747A
(es)
|
2001-05-25 |
2004-03-02 |
Human Genome Sciences Inc |
Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
|
WO2003060071A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
ES2432091T5
(es)
|
2005-03-25 |
2022-03-18 |
Gitr Inc |
Moléculas de unión GITR y usos de las mismas
|
EP3037544A1
(de)
|
2005-10-13 |
2016-06-29 |
Human Genome Sciences, Inc. |
Verfahren und zusammensetzung zur verwendung bei der behandlung von systemisch lupus erythematosus patienten mit autoantikörper-positiven leiden
|
KR101461695B1
(ko)
|
2007-05-23 |
2014-11-13 |
가부시끼가이샤 도꾸야마 |
렌즈의 코팅 장치
|
WO2009009116A2
(en)
|
2007-07-12 |
2009-01-15 |
Tolerx, Inc. |
Combination therapies employing gitr binding molecules
|
KR102025502B1
(ko)
|
2008-09-26 |
2019-09-25 |
토카겐 인크. |
유전자 요법 벡터와 시토신 디아미나아제
|
HUE049825T2
(hu)
|
2009-09-03 |
2020-10-28 |
Merck Sharp & Dohme |
Anti-GITR antitestek
|
US8956859B1
(en)
|
2010-08-13 |
2015-02-17 |
Aviex Technologies Llc |
Compositions and methods for determining successful immunization by one or more vaccines
|
MX361929B
(es)
|
2010-11-19 |
2018-12-19 |
Eisai R&D Man Co Ltd Star |
Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
JP5789206B2
(ja)
|
2011-12-08 |
2015-10-07 |
東京エレクトロン株式会社 |
ウエハ検査用インターフェース及びウエハ検査装置
|
EP3623478A1
(de)
|
2012-10-25 |
2020-03-18 |
Tocagen Inc. |
Retroviraler vektor mit mini-promoter-kassette
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
BR112016010716A8
(pt)
|
2013-11-13 |
2020-04-22 |
Novartis Ag |
dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina
|
EP4026909A1
(de)
|
2013-12-19 |
2022-07-13 |
Novartis AG |
Menschliche chimäre mesothelin-antigenrezeptoren und verwendungen davon
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
BR112016020333B1
(pt)
|
2014-03-24 |
2022-08-09 |
Novartis Ag |
Compostos orgânicos de monobactam, seus usos, composições e combinações farmacêuticas
|
WO2015157252A1
(en)
|
2014-04-07 |
2015-10-15 |
BROGDON, Jennifer |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
ES2901705T3
(es)
|
2014-06-06 |
2022-03-23 |
Bristol Myers Squibb Co |
Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
|
EP3166973B1
(de)
|
2014-07-10 |
2020-02-19 |
Universität Zürich |
Immunstimulierende monoklonale antikörper gegen das humane interleukin-2
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
AU2015292755B2
(en)
|
2014-07-21 |
2020-11-12 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
JP2017523213A
(ja)
|
2014-08-06 |
2017-08-17 |
ノバルティス アーゲー |
抗菌薬としてのキノロン誘導体
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
TWI719946B
(zh)
|
2014-08-19 |
2021-03-01 |
瑞士商諾華公司 |
使用cd123嵌合抗原受體治療癌症
|
MX2017003227A
(es)
|
2014-09-13 |
2017-12-04 |
Novartis Ag |
Terapias de combinacion de inhibidores de alk.
|
KR102590396B1
(ko)
|
2014-09-17 |
2023-10-19 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
CN114107424A
(zh)
|
2014-10-08 |
2022-03-01 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對pd-l1之抗體分子及其用途
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
WO2016097995A1
(en)
|
2014-12-16 |
2016-06-23 |
Novartis Ag |
Isoxazole hydroxamic acid compounds as lpxc inhibitors
|
EP3233918A1
(de)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Kombinationstherapien
|
IL253149B2
(en)
|
2014-12-29 |
2023-11-01 |
Novartis Ag |
Methods for preparing cells expressing a chimeric receptor antigen
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
PE20171448A1
(es)
|
2015-03-10 |
2017-10-02 |
Aduro Biotech Inc |
Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
|
WO2016164580A1
(en)
|
2015-04-07 |
2016-10-13 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
DK3280729T3
(da)
|
2015-04-08 |
2022-07-25 |
Novartis Ag |
Cd20-behandlinger, cd22-behandlinger og kombinationsbehandlinger med en cd19-kimær antigenreceptor (car)-udtrykkende celle
|
JP7114457B2
(ja)
|
2015-04-17 |
2022-08-08 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
EA201792497A1
(ru)
|
2015-06-03 |
2018-05-31 |
Бристол-Майерс Сквибб Компани |
Антитела к gitr для диагностики злокачественной опухоли
|
JP7146632B2
(ja)
|
2015-07-21 |
2022-10-04 |
ノバルティス アーゲー |
免疫細胞の有効性および増大を改善する方法
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
EP3316902A1
(de)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen tim-3
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
CR20180234A
(es)
|
2015-11-03 |
2018-09-11 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y sus usos
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
AU2016369537B2
(en)
|
2015-12-17 |
2024-03-14 |
Novartis Ag |
Antibody molecules to PD-1 and uses thereof
|
CA3008102A1
(en)
|
2015-12-18 |
2017-06-22 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
CN109069597A
(zh)
|
2015-12-22 |
2018-12-21 |
诺华股份有限公司 |
间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
|
CN117025539A
(zh)
|
2015-12-28 |
2023-11-10 |
诺华股份有限公司 |
制备嵌合抗原受体表达细胞的方法
|
KR20180100224A
(ko)
|
2016-01-11 |
2018-09-07 |
노바르티스 아게 |
인간 인터루킨-2에 대한 면역-자극 인간화 단일클론 항체, 및 이의 융합 단백질
|
WO2017140821A1
(en)
|
2016-02-19 |
2017-08-24 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
WO2017165681A1
(en)
|
2016-03-24 |
2017-09-28 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
FI3433257T3
(fi)
|
2016-03-24 |
2024-01-08 |
Novartis Ag |
Alkynyylinukleosidianalogeja ihmisen rinoviruksen estäjinä
|
AU2017278193B9
(en)
|
2016-06-10 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-GITR antibodies and uses thereof
|
SG11201810656WA
(en)
|
2016-06-14 |
2018-12-28 |
Novartis Ag |
Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
SG11201811237WA
(en)
|
2016-06-24 |
2019-01-30 |
Infinity Pharmaceuticals Inc |
Combination therapies
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
US11365252B2
(en)
|
2016-07-20 |
2022-06-21 |
University Of Utah Research Foundation |
CD229 CAR T cells and methods of use thereof
|
WO2018047109A1
(en)
|
2016-09-09 |
2018-03-15 |
Novartis Ag |
Polycyclic pyridone compounds as antivirals
|
AU2017332161B9
(en)
|
2016-09-21 |
2024-08-22 |
The United States Government As Represented By The Department Of Veterans Affairs |
Chimeric antigen receptor (car) that targets chemokine receptor CCR4 and its use
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
BR112019006781A2
(pt)
|
2016-10-07 |
2019-07-30 |
Novartis Ag |
receptores de antígeno quiméricos para o tratamento de câncer
|
WO2018073753A1
(en)
|
2016-10-18 |
2018-04-26 |
Novartis Ag |
Fused tetracyclic pyridone compounds as antivirals
|
AU2017368333A1
(en)
|
2016-12-03 |
2019-06-13 |
Juno Therapeutics, Inc. |
Methods for determining CAR-T cells dosing
|
CN116606261A
(zh)
|
2016-12-22 |
2023-08-18 |
美国安进公司 |
Kras g12c抑制剂及其使用方法
|
EP3565839A4
(de)
|
2017-01-05 |
2021-04-21 |
Gensun Biopharma Inc. |
Checkpoint-regulatorantagonisten
|
MX2019011858A
(es)
|
2017-04-03 |
2019-11-21 |
Oncologie Inc |
Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
EP3615055A1
(de)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Zellen, die einen auf bcma abzielenden chimären antigenrezeptor exprimieren, und kombinationsbehandlung mit einem gamma-sekretase-inhibitor
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
UY37718A
(es)
|
2017-05-05 |
2018-11-30 |
Novartis Ag |
2-quinolinonas triciclicas como agentes antibacteriales
|
EP3625260A1
(de)
|
2017-05-16 |
2020-03-25 |
Bristol-Myers Squibb Company |
Behandlung von krebs mit antikörpern gegen gitr-agonisten
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
AU2018275109A1
(en)
|
2017-06-01 |
2020-01-02 |
Xencor, Inc. |
Bispecific antibodies that bind CD 123 CD3
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
MX2019014268A
(es)
|
2017-06-02 |
2020-08-03 |
Juno Therapeutics Inc |
Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva.
|
CN110719799A
(zh)
|
2017-06-09 |
2020-01-21 |
俄勒冈州普罗维登斯健康与服务部 |
Cd39和cd103在鉴定用于癌症治疗的人肿瘤反应性t细胞中的应用
|
JP2020526194A
(ja)
|
2017-06-29 |
2020-08-31 |
ジュノー セラピューティクス インコーポレイテッド |
免疫療法薬と関連する毒性を評価するためのマウスモデル
|
AU2018329920B2
(en)
|
2017-09-08 |
2022-12-01 |
Amgen Inc. |
Inhibitors of KRAS G12C and methods of using the same
|
JP2021500894A
(ja)
|
2017-10-25 |
2021-01-14 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
MX2020004243A
(es)
|
2017-11-01 |
2020-09-25 |
Juno Therapeutics Inc |
Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
|
BR112020008638A2
(pt)
|
2017-11-01 |
2020-10-20 |
Juno Therapeutics Inc |
receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
|
WO2019097479A1
(en)
|
2017-11-17 |
2019-05-23 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
EP3716980A1
(de)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics, Inc. |
Verfahren zur dosieren und modulierung von genetisch veränderten zellen
|
EP3724225A1
(de)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics, Inc. |
Anti-cct5-bindende moleküle und verfahren zur verwendung davon
|
US11234977B2
(en)
|
2017-12-20 |
2022-02-01 |
Novartis Ag |
Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
|
EP3759110A1
(de)
|
2018-02-28 |
2021-01-06 |
Novartis AG |
Indol-2-carbonylverbindungen und ihre verwendung zur behandlung von hepatitis b
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
CN110305210B
(zh)
|
2018-03-27 |
2023-02-28 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
JP7266043B2
(ja)
|
2018-05-04 |
2023-04-27 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
MA52496A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
AU2019265822B2
(en)
|
2018-05-10 |
2024-07-18 |
Amgen Inc. |
KRAS G12C inhibitors for the treatment of cancer
|
EP3801769A1
(de)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Kombinationstherapie mit therapien mit chimärem antigen-rezeptor (car)
|
MA52765A
(fr)
|
2018-06-01 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
EP3801617A1
(de)
|
2018-06-01 |
2021-04-14 |
Novartis Ag |
Dosierung eines bispezifischen antikörpers, der cd123 und cd3 bindet
|
WO2019241157A1
(en)
|
2018-06-11 |
2019-12-19 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
EP3807276A2
(de)
|
2018-06-12 |
2021-04-21 |
Amgen Inc. |
Einen piperazinring umfassende kras g12c-inhibitoren und ihre verwendung zur krebsbehandlung
|
BR112020025048A2
(pt)
|
2018-06-13 |
2021-04-06 |
Novartis Ag |
Receptores de antígeno quimérico de bcma e usos dos mesmos
|
JP2021529557A
(ja)
|
2018-06-29 |
2021-11-04 |
ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. |
抗腫瘍免疫チェックポイント調節因子アンタゴニスト
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
KR20210055046A
(ko)
|
2018-08-31 |
2021-05-14 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
MX2021002690A
(es)
|
2018-09-07 |
2021-05-12 |
Pfizer |
Anticuerpos anti-avb8 y composiciones y usos de los mismos.
|
JP7273951B2
(ja)
|
2018-09-12 |
2023-05-15 |
ノバルティス アーゲー |
抗ウイルス性ピリドピラジンジオン化合物
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
AU2019350592B2
(en)
|
2018-09-29 |
2024-09-26 |
Novartis Ag |
Process of manufacture of a compound for inhibiting the activity of SHP2
|
PE20211058A1
(es)
|
2018-11-01 |
2021-06-07 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
|
BR112021008289A2
(pt)
|
2018-11-01 |
2021-10-26 |
Juno Therapeutics, Inc. |
Métodos para tratamento utilizando receptores de antígeno quimérico específico para antígeno de maturação de célula b
|
JP2022513062A
(ja)
|
2018-11-16 |
2022-02-07 |
ジュノー セラピューティクス インコーポレイテッド |
B細胞悪性腫瘍を処置するために、操作されたt細胞を投薬する方法
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7454572B2
(ja)
|
2018-11-19 |
2024-03-22 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤及びその使用方法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
KR20210117260A
(ko)
|
2018-11-30 |
2021-09-28 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법을 사용한 치료방법
|
JP2022513971A
(ja)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
AU2019403488A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
KIF18A inhibitors
|
AU2019403486A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
KIF18A inhibitors
|
AU2019404576A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
EA202192103A1
(ru)
|
2019-01-29 |
2021-12-15 |
Джуно Терапьютикс, Инк. |
Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
|
WO2020180770A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
CN113767100A
(zh)
|
2019-03-01 |
2021-12-07 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
MX2021014126A
(es)
|
2019-05-21 |
2022-01-04 |
Amgen Inc |
Formas en estado solido.
|
EP3990116A1
(de)
|
2019-06-28 |
2022-05-04 |
Gensun Biopharma Inc. |
Antitumor-antagonist bestehend aus einer mutierten tgfss1-rii-extrazellulären domäne und einem immunoglobulin-gerüst
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
US20220372018A1
(en)
|
2019-08-02 |
2022-11-24 |
Amgen Inc. |
Kif18a inhibitors
|
AU2020324963A1
(en)
|
2019-08-02 |
2022-02-24 |
Amgen Inc. |
KIF18A inhibitors
|
AU2020353055B2
(en)
|
2019-09-26 |
2024-03-07 |
Gilead Sciences, Inc. |
Antiviral pyrazolopyridinone compounds
|
US20240190862A1
(en)
|
2019-10-24 |
2024-06-13 |
Amgen Inc. |
Epoxyamides as kras g12c and kras g12d inhibitors and methods of using the same
|
AU2020377925A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
US11566007B2
(en)
|
2019-11-04 |
2023-01-31 |
Revolution Medicines, Inc. |
Ras inhibitors
|
TW202132315A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras 抑制劑
|
MX2022005525A
(es)
|
2019-11-08 |
2022-06-08 |
Revolution Medicines Inc |
Compuestos de heteroarilo bicíclicos y usos de estos.
|
AU2020383535A1
(en)
|
2019-11-14 |
2022-05-05 |
Amgen Inc. |
Improved synthesis of KRAS G12C inhibitor compound
|
TW202132296A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Kras g12c抑制劑化合物之改善的合成
|
BR112022010206A2
(pt)
|
2019-11-26 |
2022-11-29 |
Novartis Ag |
Receptores de antígeno quiméricos e usos dos mesmos
|
WO2021108613A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
EP4065231A1
(de)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Kovalente ras-inhibitoren und verwendungen davon
|
EP4087611A1
(de)
|
2020-01-07 |
2022-11-16 |
Revolution Medicines, Inc. |
Shp2-inhibitordosierung und verfahren zum behandeln von krebs
|
WO2021163618A1
(en)
|
2020-02-14 |
2021-08-19 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
JP2023515211A
(ja)
|
2020-02-27 |
2023-04-12 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
TW202146452A
(zh)
|
2020-02-28 |
2021-12-16 |
瑞士商諾華公司 |
結合cd123和cd3之雙特異性抗體的給藥
|
BR112022017156A2
(pt)
|
2020-03-06 |
2022-11-08 |
Regeneron Pharma |
Anticorpo isolado ou fragmento de ligação, molécula polinucleotídica isolada, vetor, célula hospedeira isolada, composição farmacêutica, método de tratamento de câncer, e, uso de um anticorpo
|
KR20230009386A
(ko)
|
2020-04-10 |
2023-01-17 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
|
CA3183032A1
(en)
|
2020-06-18 |
2021-12-23 |
Mallika Singh |
Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
IL301298A
(en)
|
2020-09-15 |
2023-05-01 |
Revolution Medicines Inc |
Indole derivatives as RAS inhibitors in cancer therapy
|
EP4243857A1
(de)
|
2020-11-13 |
2023-09-20 |
Novartis AG |
Kombinationstherapien mit zellen zur expression des chimären antigenrezeptors (car)
|
EP4259149A1
(de)
|
2020-12-08 |
2023-10-18 |
Infinity Pharmaceuticals, Inc. |
Eganelisib zur verwendung bei der behandlung von pd-l1-negativem krebs
|
US20240051956A1
(en)
|
2020-12-22 |
2024-02-15 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
TW202309052A
(zh)
|
2021-05-05 |
2023-03-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
CN117616031A
(zh)
|
2021-05-05 |
2024-02-27 |
锐新医药公司 |
用于治疗癌症的ras抑制剂
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ras阻害剤及びその使用
|
WO2022254337A1
(en)
|
2021-06-01 |
2022-12-08 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
EP4351595A1
(de)
|
2021-06-07 |
2024-04-17 |
Providence Health & Services - Oregon |
Cxcr5, pd-1 und icos mit expression tumorreaktiver cd4-t-zellen und deren verwendung
|
TW202328090A
(zh)
|
2021-09-08 |
2023-07-16 |
美商雷度納製藥公司 |
Papd5及/或papd7抑制劑
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
TW202342474A
(zh)
|
2022-02-14 |
2023-11-01 |
美商基利科學股份有限公司 |
抗病毒吡唑并吡啶酮化合物
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024031091A2
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024129778A2
(en)
|
2022-12-13 |
2024-06-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
WO2024206858A1
(en)
|
2023-03-30 |
2024-10-03 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
US20240352036A1
(en)
|
2023-04-14 |
2024-10-24 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
WO2024216048A1
(en)
|
2023-04-14 |
2024-10-17 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|